View Item 

Show simple item record

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
dc.contributor.authorPai, AB
dc.contributor.authorMeyer, DE
dc.contributor.authorBales, BC
dc.contributor.authorCotero, VE
dc.contributor.authorPai, MP
dc.contributor.authorZheng, N
dc.contributor.authorJiang, W
dc.date.accessioned2017-06-16T20:13:23Z
dc.date.available2018-07-09T17:42:25Zen
dc.date.issued2017-05
dc.identifier.citationPai, AB; Meyer, DE; Bales, BC; Cotero, VE; Pai, MP; Zheng, N; Jiang, W (2017). "Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations." Clinical and Translational Science 10(3): 194-200.
dc.identifier.issn1752-8054
dc.identifier.issn1752-8062
dc.identifier.urihttps://hdl.handle.net/2027.42/137448
dc.publisherWiley Periodicals, Inc.
dc.titlePerformance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137448/1/cts12443_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137448/2/cts12443.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137448/3/cts12443-sup-0003-figureS2.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137448/4/cts12443-sup-0002-figureS1.pdf
dc.identifier.doi10.1111/cts.12443
dc.identifier.sourceClinical and Translational Science
dc.identifier.citedreferenceEuropean Medicines Agency. Reflection paper on non‐clinical studies for generic nanoparticle iron medicinal product applications. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/04/WC500105048.pdf. Accessed 6_1_16 ( 2011 )
dc.identifier.citedreferenceToblli, J.E., Cao, G., Oliveri, L. & Angerosa, M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm. Allergy Drug Targets 11, 66 – 78 ( 2012 ).
dc.identifier.citedreferenceStein, J., Dignass, A. & Chow, K.U. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr. Med. Res. Opin. 28, 241 – 243 ( 2012 ).
dc.identifier.citedreferenceKuo, K.L., Hung, S.C., Lee, T.S. & Tarng, D.C. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J. Am Soc. Nephrol. 25, 2596 – 2606 ( 2014 ).
dc.identifier.citedreferencehttp://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/078215s000ltr.pdf accessed 6_1_16
dc.identifier.citedreferencehttps://www.drugs.com/pro/nulecit.html accessed 6_1_16
dc.identifier.citedreferencehttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358142.pdf accessed 6_1_16
dc.identifier.citedreferenceShi, Q. et al. Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses. Contrast Media Mol. Imaging 8, 281 – 288 ( 2013 ).
dc.identifier.citedreferenceEsposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. & Cabantchik, Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102, 2670 – 2677 ( 2003 ).
dc.identifier.citedreferenceBurkitt, M.J., Milne, L. & Raafat, A. A simple, highly sensitive and improved method for the measurement of bleomycin‐detectable iron: the ‘catalytic iron index’ and its value in the assessment of iron status in haemochromatosis. Clin. Sci. (Lond). 100, 239 – 247 ( 2001 ).
dc.identifier.citedreferenceBreuer, W., Ermers, M.J.J., Pootrakul, P., Abramov, A., Hersko, C. & Cabantchik, Z.I. Desferrioxamine‐chelatable iron, a component of serum non‐transferrin‐bound iron, used for assessing chelation therapy. Blood 97, 792 – 789 ( 2001 ).
dc.identifier.citedreferenceSu, B.L. et al. Fl‐DFO molecules mesoporous silica materials: highly sensitive and selective nanosensor for dosing with iron ions. J. Colloid Interface Sci. 358, 136 – 145 ( 2011 ).
dc.identifier.citedreferenceKoba, M., Słomka, A., Bączek, T., Marszałł, M.P. & Zekanowska, E. Ability to determine the desferrioxamine‐chelatable iron fractions of nontransferrin‐bound iron using HPL. J. Sep. Sci. 36, 665 – 669 ( 2013 ).
dc.identifier.citedreferenceTesoro, A., Novakovic, J., Thiessen, J.J. & Spino, M. Validated HPLC assay for iron determination in biological matrices based on ferrioxamine formation. J. Chromatogr. Analyt. Technol. Biomed. Life Sci. 823, 177 – 183 ( 2005 ).
dc.identifier.citedreferenceCabantchik, Z.I. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front. Pharmacol. 13, 45 ( 2014 ).
dc.identifier.citedreferenceBrookhart, M.A., Freburger, J.K., Ellis, A.R., Wang, L., Winkelmayer, W.C. & Kshirsagar, A.V. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J. Am. Soc. Nephrol. 24, 1151 – 1158 ( 2013 ).
dc.identifier.citedreferenceLee, E.S., Park, B.R., Kim, J.S., Choi, G.Y., Lee, J.J. & Lee, I.S. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr. Med. Res. Opin. 29, 141 – 147 ( 2013 ).
dc.identifier.citedreferenceSeligman, P.A. et al. Single‐dose pharmacokinetics of sodium ferric gluconate complex in iron‐deficient subjects. Pharmacotherapy 24, 574 – 583 ( 2004 ).
dc.identifier.citedreferenceOnken, J.E. et al. Ferric carboxymaltose in patients with iron‐deficiency anemia and impaired renal function: the REPAIR‐IDA trial. Nephrol. Dial. Transplant. 29, 833 – 842 ( 2014 ).
dc.identifier.citedreferenceBreuer, W., Ronson, A., Slotki, I.N., Abramov, A., Hershko, C. & Cabantchik, Z.I. The assessment of serum nontransferrin‐bound iron in chelation therapy and iron supplementation. Blood 95, 2975 – 2982 ( 2000 ).
dc.identifier.citedreferenceCharytan, D.M. et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J. Am. Soc. Nephrol. 26, 1238 – 1247 ( 2015 ).
dc.identifier.citedreferenceDanielson, B.G. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am Soc. Nephrol. 15, S93 – S98 ( 2004 ).
dc.identifier.citedreferenceJahn, M.R. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78, 480 – 491 ( 2011 ).
dc.identifier.citedreferenceDuncan, R. & Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharm. 8, 2101 – 2141 ( 2011 ).
dc.identifier.citedreferenceYang, Y., Shah, R.B., Faustino, P.J., Raw, A., Yu, L.X. & Khan, M.A. Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate. J. Pharm. Sci. 99, 142 – 153 ( 2010 ).
dc.identifier.citedreferencePai, A.B., Boyd, A.V., McQuade, C.R., Harford, A., Norenberg, J.P. & Zager, P.G. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and sucrose in patients undergoing hemodialysis. Pharmacotherapy 27, 343 – 350 ( 2007 ).
dc.identifier.citedreferenceBalakrishnan, V.S. et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur. J. Clin. Invest. 39, 489 – 496 ( 2009 ).
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cts12443_am.pdf
Size:
1.012MB
Format:
PDF
View/Open
Name:
cts12443.pdf
Size:
511.3KB
Format:
PDF
View/Open
Name:
cts12443-sup-0003-figureS2.pdf
Size:
89.58KB
Format:
PDF
View/Open
Name:
cts12443-sup-0002-figureS1.pdf
Size:
16.80KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.